Earnings season should provide a fresh view of the U.S. economy and may shake the stock market out of its summer doldrums.
Douglas Roberts, founder and chief investment strategist at ChannelCapitalResearch.com and Mike Williams, founder and managing partner at Genesis Asset Management shared their opposing market views and advised investors on where they should put their money.
Shares of Human Genome Sciences are up on the day Thursday and bringing in option traders. HGSI is up more than 4 percent to $3.15 in early afternoon trading, well off the $3.44 high of the day that was reached just after the open.
In less than two weeks, there've been four pretty significant events in biopharma. And, hopefully, after ADA things will begin to settle down a bit for the summer.
The cost of drugs was a hot topic at ASCO this year, especially with the release of the big test results combining two very expensive treatments for lung cancer. The study showed using Avastin from Roche and Genentech and a pill, Tarceva, from OSI Pharmaceuticals, Roche and Genentech slowed down progression of the disease by a little more than a month.
I'm juggling the Amylin Pharmaceuticals proxy fight, then ASCO (American Society of Clinical Oncology), then the Biogen Idec shareholder meeting and then the ADA (American Diabetes Association) meeting all within a week-and-a-half.
It's going to be a crazy busy, stressful couple of weeks. A shareholder meeting, a medical meeting, then another shareholder meeting and finally another medical meeting.
With the latest wave of disclosures hitting the Street, we’re learning about recent moves made by two billionaires. Should you trade in their wake?
Billionaire activist investor (It seems it's become almost de rigueur to put those three words before his name) Carl Icahn is apparently so busy waging a proxy fight against biotechs Amylin Pharmaceuticals and Biogen Idec that he hasn't posted a new blog entry in nearly a month.
The Lightning Round is extended in this CNBC.com exclusive feature.
Shortly after Eli Lilly reported way better than expected earnings this morning, Amylin Pharmaceuticals fired a new salvo in its escalating proxy battle with billionaire activist investor Carl Icahn.
Stocks ended a rocky session higher Thursday as investors were encouraged by JPMorgan's results and techs rallied amid anticipation of better results from Google after the bell.
An early pop fizzled Thursday as investors digested a mixed bag of economic and earnings news. Banks were mixed as techs gained.
Futures pointed to a higher open Thursday as investors shrugged off some dismal data points, choosing to focus on a drop in the headline jobless-claims number.
JPMorgan Chase could rule the day Thursday. Traders expect the stock and Treasury markets to take their cue from the bank's first quarter earnings report and forward comments.
Following are the “Fast & Furious” trades - hot ways to play tomorrow's market moving events.
Investors are eager to hear results from Amylin and Biogen, Thursday. It seems the future of both firms could lie in the hands of Fast Money friend Carl Icahn!
Eric writes, “I know Karen likes some of the names in biotech. Would she be a buyer of Biogen ahead of earnings this week?”
After a five-week rally, stocks face one of their toughest challenges yet - a very nasty earnings season.
Once again, activist investor Carl Icahn turns to Fast Money to set the record straight on all the rumors surrounding his wheeling and dealing.